- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.08. | BIODLINK-B Interim Loss RMB58.52 million vs Profit a Year Ago | 1 | AASTOCKS | ||
| 21.08. | BIODLINK-B (01875): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | - | HKEx | ||
| 11.08. | BIODLINK-B (01875): CHANGE OF COMPANY LOGO | 1 | HKEx | ||
| 10.07. | BIODLINK-B (01875): DATE OF BOARD MEETING | 2 | HKEx | ||
| 26.06. | BIODLINK-B (01875): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026 | 5 | HKEx | ||
| 26.06. | BIODLINK-B (01875): CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | 2 | HKEx | ||
| 17.06. | BIODLINK-B (01875): CONNECTED TRANSACTION ENTERING INTO OF PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT | 1 | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 11.06. | BIODLINK-B (01875): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 11 JUNE 2026 | 1 | HKEx | ||
| 04.06. | BIODLINK-B (01875): FORM OF PROXY | - | HKEx | ||
| 04.06. | BIODLINK-B (01875): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 04.06. | BIODLINK-B (01875): RETIREMENT OF EXISTING AUDITOR AND PROPOSED APPOINTMENT OF NEW AUDITOR | - | HKEx | ||
| 04.06. | BIODLINK-B (01875): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, PROPOSED CHANGE OF AUDITOR, AND NOTICE ... | - | HKEx | ||
| 03.06. | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS | - | HKEx | ||
| 02.06. | BIODLINK-B (01875): VOLUNTARY ANNOUNCEMENT | - | HKEx | ||
| 26.05. | BIODLINK-B (01875): FORM OF PROXY | 2 | HKEx | ||
| 26.05. | BIODLINK-B (01875): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 26.05. | BIODLINK-B (01875): CONTINUING CONNECTED TRANSACTION CDMO MASTER SERVICES AGREEMENT AND NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 26.05. | BIODLINK-B (01875): CONTINUING CONNECTED TRANSACTIONS | - | HKEx | ||
| 29.04. | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 3 | HKEx | ||
| 28.04. | BIODLINK-B (01875): (1) RESIGNATION OF DIRECTORS AND CHAIRPERSON OF THE BOARD; (2) APPOINTMENTS OF DIRECTORS, CHAIRPERSON OF THE BOARD AND CHANGES IN ... | - | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 77,74 | -0,65 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,560 | +14,46 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,74 % | Qiagen sorgt für Gesprächsstoff, Rheinmetall bleibt unter Druck, Nvidia zeigt sich freundlicher und Siemens Energy profitiert von neuer Zuversicht im KI-Segment | Die Zinserhöhung der Fed sowie die Aussicht auf weitere Zinsschritte in der nahen Zukunft scheinen die Märkte erstaunlich schnell verdaut zu haben. Statt weiterer Kursstürze gab es am Donnerstag dann... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,780 | +7,01 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| DECOY THERAPEUTICS | 3,100 | +21,81 % | Decoy Therapeutics, Inc: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding | Next-Generation D-MAVs Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility
... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,050 | +2,02 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| AMYLYX PHARMACEUTICALS | 33,000 | +1,88 % | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 300,95 | +0,62 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 41,530 | -1,35 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,480 | -0,40 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| MAZE THERAPEUTICS | 28,340 | +26,57 % | Maze Therapeutics auf Konferenz von H.C. Wainwright: Pipeline vor entscheidenden Tests | ||
| ABSCI | 10,685 | +8,81 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MODERNA | 159,20 | +5,56 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| VERA THERAPEUTICS | 36,250 | +5,84 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,115 | +1,27 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock |
Das Unternehmen BIODLINK INTERNATIONAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.